Karin A.J. De Winter

Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial

Stephanie M. de Boer, Melanie Powell, Linda Mileshkin et al. · The Lancet Oncology · 2018 · 623 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Survival after relapse in patients with endometrial cancer: results from a randomized trial☆

Carien L. Creutzberg, Wim L.J. van Putten, P. Koper et al. · Gynecologic Oncology · 2003 · 372 citations

Medicine, Gynecology, Oncology +8

Outcome of High-Risk Stage IC, Grade 3, Compared With Stage I Endometrial Carcinoma Patients: The Postoperative Radiation Therapy in Endometrial Carcinoma Trial

Carien L. Creutzberg, Wim L.J. van Putten, Carla C. Wárlám-Rodenhuis et al. · Journal of Clinical Oncology · 2004 · 277 citations · Full text

Medicine, Oncology, Surgery +17

Postoperative radiotherapy for Stage 1 endometrial carcinoma: Long-term outcome of the randomized PORTEC trial with central pathology review

Astrid N. Scholten, Wim L.J. van Putten, H Beerman et al. · International Journal of Radiation Oncology*Biology*Physics · 2005 · 244 citations

Medicine, Oncology, Radiation Oncology +11

The morbidity of treatment for patients with stage I endometrial cancer: results from a randomized trial

Carien L. Creutzberg, Wim L.J. van Putten, P. Koper et al. · International Journal of Radiation Oncology*Biology*Physics · 2001 · 194 citations

Medicine, Gynecology, Oncology +6